Want to see ATNM full AI Analyst Report?
Top Page
Actinium Pharmaceuticals
(ATNM)
Select Model
Select Model
Rating:58Neutral
Price Target:
$1.50
▲(38.89% Upside)
Action:Reiterated
Date:09/09/26
The score is driven primarily by mixed financial performance: a notable TTM improvement in revenue and net income and low leverage are outweighed by continued heavy negative operating/free cash flow. Technicals are supportive with price above major moving averages and a positive MACD, but the elevated RSI raises near-term risk. Valuation looks favorable on a low P/E, while corporate events are balanced between IP/manufacturing progress and ongoing listing compliance risk.
Positive Factors
Actimab-A IP and capacity
Broader patent protection can extend the commercial opportunity and defensibility of Actimab-A across myeloid malignancies and potential solid-tumor applications. Additional manufacturing capacity also supports clinical execution, helping the program advance toward late-2026 and 2027 milestones.
Negative Factors
Persistent cash burn
Deeply negative operating and free cash flow show that reported positive net income is not translating into self-funded operations. Continued cash burn could require additional financing or strategic monetization, creating ongoing funding pressure while clinical development and regulatory work continue.
Read all positive and negative factors
Positive Factors
Negative Factors
Actimab-A IP and capacity
Broader patent protection can extend the commercial opportunity and defensibility of Actimab-A across myeloid malignancies and potential solid-tumor applications. Additional manufacturing capacity also supports clinical execution, helping the program advance toward late-2026 and 2027 milestones.
Read all positive factors
Actinium Pharmaceuticals (ATNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.67M
Dividend YieldN/A
Average Volume (3M)147.19K
Price to Earnings (P/E)3.4
Beta (1Y)1.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume84,184
30 Day Avg. Volume147,190
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)$35.00M
Actinium Pharmaceuticals Business Overview & Revenue Model
Company Description
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leadi...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Actinium Pharmaceuticals’ ability to generate recurring product revenue from commercial drug sales is null. The company’s economic model is primarily driven by (1) raising capital through equity and/o...
Actinium Pharmaceuticals Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.09M | 90.00K | 0.00 | 81.00K | 1.03M | 1.14M |
| Gross Profit | 35.48M | 90.00K | -811.00K | 81.00K | 1.03M | 620.00K |
| EBITDA | 12.18M | -33.07M | -37.43M | -48.03M | -32.32M | -24.25M |
| Net Income | 11.31M | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M |
Balance Sheet | ||||||
| Total Assets | 40.16M | 51.77M | 76.90M | 81.44M | 114.19M | 80.39M |
| Cash, Cash Equivalents and Short-Term Investments | 36.47M | 48.00M | 72.90M | 76.68M | 108.91M | 77.83M |
| Total Debt | 1.34M | 1.69M | 1.57M | 2.11M | 2.58M | 310.00K |
| Total Liabilities | 9.86M | 43.94M | 44.14M | 45.07M | 47.71M | 6.84M |
| Stockholders Equity | 30.30M | 7.83M | 32.76M | 36.38M | 66.48M | 73.55M |
Cash Flow | ||||||
| Free Cash Flow | -23.25M | -24.68M | -33.08M | -47.49M | 8.28M | -21.00M |
| Operating Cash Flow | -22.66M | -24.58M | -33.07M | -47.34M | 8.64M | -20.87M |
| Investing Cash Flow | -584.00K | -104.00K | -11.00K | -153.00K | -366.00K | -133.00K |
| Financing Cash Flow | -217.00K | -217.00K | 29.32M | 14.87M | 23.11M | 35.22M |
Actinium Pharmaceuticals Technical Analysis
Positive
1.08
Price Trends
0.95
Positive
1.06
Positive
1.16
Positive
Market Momentum
0.05
Negative
71.10
Negative
72.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Positive. The current price of 1.08 is above the 20-day moving average (MA) of 1.05, above the 50-day MA of 0.95, and below the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 71.10 is Negative, neither overbought nor oversold. The STOCH value of 72.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATNM.
Actinium Pharmaceuticals Risk Analysis
Actinium Pharmaceuticals disclosed 68 risk factors in its most recent earnings report. Actinium Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Actinium Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $22.78M | -0.52 | -165.71% | ― | ― | 77.68% | |
58 Neutral | $38.67M | 3.42 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $16.79M | -0.46 | -708.20% | ― | ― | 30.16% | |
44 Neutral | $44.58M | -0.39 | 411.46% | ― | -51.03% | -35.20% | |
43 Neutral | $21.34M | -2.52 | -56.96% | ― | -56.64% | 64.88% | |
42 Neutral | $9.45M | -0.06 | -443.08% | ― | ― | 75.09% |
* Healthcare Sector Average
ATNM
Actinium Pharmaceuticals
1.23
-0.38
-23.60%
CLRB
Cellectar Biosciences
2.37
-2.64
-52.70%
PDSB
PDS Biotechnology
0.29
-0.94
-76.18%
GTBP
GT Biopharma
5.98
-14.02
-70.10%
MRKR
Marker Therapeutics
1.21
0.30
33.11%
CELU
Celularity
1.44
-0.91
-38.72%
Actinium Pharmaceuticals Corporate Events
Business Operations and StrategyDelistings and Listing ChangesProduct-Related AnnouncementsRegulatory Filings and Compliance
Actinium Pharmaceuticals Expands Actimab-A Patents, Manufacturing Capacity
Positive
Aug 14, 2026
On August 14, 2026, Actinium Pharmaceuticals announced significant progress in its Actimab-A program, reporting newly issued patents that broaden protection for its use in treating myeloid hematologic malignancies and extending its anti-CD33 platf...
Delistings and Listing ChangesRegulatory Filings and Compliance
Actinium Submits NYSE Compliance Plan to Restore Listing
Negative
Jun 18, 2026
On June 18, 2026, Actinium Pharmaceuticals submitted a compliance plan to the NYSE American after receiving notice on May 27, 2026, that it was not meeting continued listing standards related to minimum stockholders’ equity. The plan outline...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.